Actinogen Medical (ASX:ACW) has requested an immediate trading halt on its securities to enable a review and analysis of clinical trial results for its XanaMIA phase 2b/3 trial, according to a filing submitted to ASX Listings Supervision on 13 November 2026.
Key Points
- Actinogen Medical requested an immediate trading halt effective 13 November 2026.
- The halt was requested to enable a review and analysis of clinical trial results for the XanaMIA phase 2b/3 trial.
- The trading halt is anticipated to remain in place until the earlier of a material announcement or 10:00 am AEDT on Tuesday, 17 November 2026.
- The company stated it is not aware of any reason why the trading halt should not be granted.
Trading Halt Request Details
Actinogen Medical Limited, trading as Actinogen Medical (ACN 086 778 476), submitted its trading halt request to the Senior Adviser Listings Supervision in Sydney on 13 November 2026. The request was made pursuant to ASX Listing Rule 17.1 and was authorised by the Board of Actinogen Medical. Company Secretary Peter Webse signed the correspondence. The company disclosed it is not aware of any other information necessary to inform the market about the trading halt beyond what was stated in the filing.
XanaMIA Phase 2b/3 Clinical Trial
The trading halt was specifically requested to allow the company to conduct a review and analysis of clinical trial results for the XanaMIA phase 2b/3 trial. The filing does not disclose the nature, content, or outcome of the clinical trial results. No further details regarding the XanaMIA trial, including its therapeutic focus, trial design, patient population, or any findings, were included in the filing. The company indicated that a material announcement is anticipated in connection with the review process.
Trading Halt Duration and Conditions
Actinogen Medical stated that the trading halt is expected to remain in place until the earlier of the release of a material announcement or no later than 10:00 am Australian Eastern Daylight Time on Tuesday, 17 November 2026. The company confirmed it is not aware of any reason why ASX Limited should not grant the requested halt. No further conditions or contingencies relating to the duration or lifting of the trading halt were disclosed in the filing.





Please wait processing your request...